Form 4: Zevra Therapeutics Director Wendy Dixon Awarded Stock Options

Director Wendy L. Dixon received stock options for 39,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89 on May 13, 2024, as compensation for board service.

Summary

• Wendy L. Dixon, a director of Zevra Therapeutics, Inc., was granted stock options to purchase 39,200 shares of the company's common stock on May 13, 2024.
• The exercise price for these options is $4.89 per share, which was the closing price of ZVRA on the Nasdaq Global Select Market on the grant date.
• The options were awarded as compensation for Dixon's service on the company's board of directors, in accordance with the ninth amended and restated non-employee director compensation policy.
• The options vest on the earlier of (i) the first anniversary of the grant date (May 13, 2025), (ii) one day prior to the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject to continued service on the board.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice. It's a neutral event, but positive in the sense that it incentivizes the director.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

NA

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders and incentivizing them to increase company value.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, performance, and board structure.
• Comparing Zevra's director compensation to that of similar-sized biotech companies like BioCryst Pharmaceuticals or Amicus Therapeutics would provide a better benchmark.
• Typical director compensation packages include a mix of cash retainers, equity grants, and committee fees.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's contributions lead to improved company performance.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates